Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Rituximab 3Immunoglobulin G 3Everolimus 3Disulfides 3Cyclosporine 3mogamulizumab 2Whole-Body Irradiation 2Tacrolimus 2Photopheresis 2Mycophenolic Acid 2Methotrexate 2Lenalidomide 2Gene Expression Profiling 2Etoposide 2Cyclophosphamide 2Busulfan 2Bortezomib 2veliparib 1navitoclax 1magrolimab 1liposomal doxorubicin 1indolepropanol phosphate 1fludarabine 1flt3 ligand protein 1ethanolamine oleate 1durvalumab 1carmustine, poliferprosan 20 drug combination 1alvocidib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sezary Syndrome × Aclarubicin × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡